Quality assurance of radiotherapy in the ongoing EORTC 1420 “Best of” trial for early stage oropharyngeal, supraglottic and hypopharyngeal carcinoma: results of the benchmark case procedure

J-J Stelmes1*†, E. Vu2†, V. Grégoire3, C. Simon4, E. Clementel5†, J. Kazmierska6, W. Grant7, M. Ozsahin4, M. Tomsej8, L. Vieillevigne9, C. Fortpied5, E. C. Hurkmans10, A. Branquinho11, N. Andratschke12, F. Zimmermann13 and D.-C. Weber14,15

Abstract

Introduction: The current phase III EORTC 1420 Best-of trial (NCT02984410) compares the swallowing function after transoral surgery versus intensity modulated radiotherapy (RT) in patients with early-stage carcinoma of the oropharynx, supraglottis and hypopharynx. We report the analysis of the Benchmark Case (BC) procedures before patient recruitment with special attention to dysphagia/aspiration related structures (DARS).

Materials and methods: Submitted RT volumes and plans from participating centers were analyzed and compared against the gold-standard expert delineations and dose distributions. Descriptive analysis of protocol deviations was conducted. Mean Sorensen-Dice similarity index (mDSI) and Hausdorff distance (mHD) were applied to evaluate the inter-observer variability (IOV).

Results: 65% (23/35) of the institutions needed more than one submission to achieve Quality assurance (RTQA) clearance. OAR volume delineations were the cause for rejection in 53% (40/76) of cases. IOV could be improved in 5 out of 12 OARs by more than 10 mm after resubmission (mHD). Despite this, final IOV for critical OARs in delineation remained significant among DARS by choosing an aleatory threshold of 0.7 (mDSI) and 15 mm (mHD).

Conclusions: This is to our knowledge the largest BC analysis among Head and neck RTQA programs performed in the framework of a prospective trial. Benchmarking identified non-common OARs and target delineations errors as the main source of deviations and IOV could be reduced in a significant number of cases after this process. Due to the substantial resources involved with benchmarking, future benchmark analyses should assess fully the impact on patients’ clinical outcome.

Keywords: EORTC 1420 Best-of trial, Swallowing, Organs at risk, Benchmark case

*Correspondence: Jean-Jacques.Stelmes@eoc.ch
†J.-J. Stelmes and E. Vu contributed equally to this work
1 Radiation Oncology Department, Oncology Institute of Southern Switzerland, Via Athos Gallino 12, 6500 Bellinzona, Switzerland
Full list of author information is available at the end of the article

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Highlights
First BC analysis evaluating delineation of swallowing organs, planning volume, and planning variations.

Introduction
Due to the emergence of HPV related oropharyngeal cancer and the increase in survival over the past decades, quality of life and in particular preservation of swallowing function becomes of paramount importance [1, 2]. Thus, novel strategies such as intensity modulated radiation therapy (IMRT) with defined constraints to dysphagia/aspiration related structures (DARS) and trans-oral surgery have been developed to provide better functional outcome whilst preserving treatment efficacy [3, 4]. A recent randomized phase III trial evaluated a dysphagia optimized intensity modulated radiotherapy (Do-IMRT) in comparison to a standard IMRT approach: The authors could show that a significantly reduced dose to the pharyngeal constrictor muscles (PCM) lead to an improvement in MDADI scores [5]. However, there is a lack of evidence to guide the choice between these two treatment options. The EORTC 1420 Best-of trial (NCT02984410) has been developed to specifically answer the question of functional equivalence between these two treatments [6]. The primary endpoint is the patient reported swallowing function over the first year evaluated by the MD Anderson Dysphagia Inventory [7].

As aberrations of the radiotherapy (RT) protocols can influence trial results [8, 9] all EORTC trials involving RT, have a dedicated trial specific Quality Assurance (RTQA) program [10,11,12] in order to increase validation of the results [13, 14].

Thus, as part of such a program, participating institutions are required to submit a benchmark case (BC) prior to patient enrollment. Benchmarking assesses sources of variation in delineation and treatment planning and ensures that the specific delineation and dose/volume guidelines for a given trial are correctly understood.

The BC in this trial is based on a selected case which fulfills the inclusion criteria of the trial. The RT volumes and corresponding reference plan have been created by experts in the field of Head and neck cancer (HNC) and compared to the single institution (RT volumes and RT plan). As swallowing function is the primary endpoint, special attention is required in delineating the DARS in reference to published guidelines [15].

The aim of this study was to investigate the performances of the participating institutions in the trial with respect to RT planning and assess the inter-observer variability (IOV). Finally, we aimed to evaluate the effectiveness of the BC procedure in reducing IOV across participating institutions. To our knowledge, this is the largest benchmark case evaluation of a currently ongoing phase III HNC trial with a specific dedication to DARS variability.

Materials and methods
A case summary including MRI screenshots were sent to the institutions. The detailed case description can be found as supplemental material. The first step of the exercise consisted of contouring all requested structures of the protocol and sending them back for revision. After volume approval, the institutions were invited to create a treatment plan according to protocol instructions (Chapter 4.5). Three radiation oncologists (J.K; W.G; M.O) specialized in head and neck cancer (ROSHNC) as two medical physicists (M.T; L.V) were previously elected to assess these submissions. Vodca RT software package (Visualization and Organization of Data for Cancer Analysis, Medical Software Solutions GmbH; Hagendorn Switzerland) was used for review.

The RTQA experts verified each investigator delineation and dose planning against a previously defined gold standard (GS). In this analysis, GS was made based on the following process: First, contouring of the BC was done separately by each ROSHNC based on pre-defined guidelines [15]. In a second step, a comparison was made, and eventual discrepancies discussed during a dedicated meeting. This process was repeated until each reviewer agreed on every single volume.

Volume definitions and dose prescriptions:
The therapeutic volume included the primary tumor and in case of N1 disease the positive lymph node. The precise contouring instructions including margins were based on current international guidelines [16]. The prophylactic volume included all nodal areas at risk for microscopic infiltration in addition to the therapeutic volume. Selection of elective lymph node stations were based on the publication by Biau et al. [17]. Unilateral irradiation was requested in case the tumor was more than 1 cm away from midline. IMRT with a simultaneous integrated boost (SIB) was mandatory. Sixty-six and or 70 Gy (T2 tumor and N1-node) in 2 Gy per fraction with 6 fractions/week was applied to the therapeutic target volumes. The elective volumes received a total dose of 54.45 Gy (T1 Tumor) and 56 Gy (T2 and N1-node) respectively. Furthermore, also for organ at risks, clear instructions on delineation were specified in the protocol [15].

Per protocol every criterion was classified in acceptable or unacceptable variation according the Global Harmonization Group Guidelines [18, 19]. Concise feedback was given and in case of unacceptable deviations, a resubmission with the needed changes was requested. If all parameters were protocol conformal or within guidelines-defined limits of acceptability, the benchmark
procedure was considered completed. A summary of the predefined review criteria can be found in the supplementary material.

Review results by the RTQA experts were collected in an Excel spreadsheet and summary statistics about global RTQA performance was calculated. Furthermore, in order to evaluate IOV, the mean Sørensen-Dice Similarity Index (mDSI) and the mean percentile Hausdorff distance (mHD) were calculated retrospectively using MIM Software Inc, Cleveland, Ohio, USA, Version 6.9.2. The mDSI, also called the overlap index, is based upon the formula:

\[ DSI = 2 \times \frac{A \cap B}{A \cup B} \]

with A and B representing the volumes of the contoured region of interest performed by the expert and one of the institutions, respectively. Values close to 1 indicate similar contours [20]. The HD measures the largest minimal distance between two boundaries. The ideal case with perfect superimposition corresponds to a HD equal to zero. Means and standard deviations were calculated for Dice and HD indexes and means and ranges for doses to OARs. Descriptive statistics and plots were generated using SAS software (SAS Institute Inc., Cary, NC, USA) [21].

**Results**

Thirty-five centers have participated in the EORTC 1420 BC analysis. Sixty-five percent (23/35) of them needed more than one submission (2, 1–4). In total, the RTQA intervention has detected 76 unacceptable deviations. Among them, OAR delineations were the cause for rejection in 53% (40/76) followed by inadequate target delineations in 35% (27/76). Lastly, concerning planning deviations, non-fulfillment of the given dose-constraints was notified in 12% (9/76). However, at a single evaluation, we found that elective volume delineation (prophylactic PTV), resulted as the major cause of rejection in 24% (19/76). Among OARs, pharyngeal constrictor muscles (PCM) (8/76) were the most frequent organs. A detailed table can be found as supplementary material.

**Table 1** Comparison of mDSI/mHD index evaluation for initially rejected and finally accepted volumes

| Volume                                      | First (SD) | Final (SD) | Difference (SD) | First (SD) | Final (SD) | Difference (SD) |
|---------------------------------------------|------------|------------|-----------------|------------|------------|-----------------|
| Planning organ-at-risk volume of the brainstem (3) | 0.74 (0.16) | 0.75 (0.14) | 0.01 (0.02) | 8.94 (4.26) | 7.88 (3.38) | 1.1 (1.1) |
| Cervical esophagus (4)                      | 0.49 (0.10) | 0.33 (0.16) | -0.16 (0.13) | 27.22 (11.98) | 18.83 (8.44) | -8.4 (14.0) |
| Cricoid pharyngeal inlet (5)                | 0.36 (0.22) | 0.38 (0.09) | 0.03 (0.20) | 13.42 (6.75) | 13.19 (3.87) | -0.2 (9.6) |
| Contralateral sub-mandibular gland (1)     | 0.83 (0.12) | 0.83 (0.12) | 0.00 (0.00) | 5.37 (0.00) | 5.37 (0.00) | 0.0 (0.0) |
| Extended oral cavity—PTV (5)               | 0.76 (0.02) | 0.84 (0.08) | 0.08 (0.06) | 26.36 (4.22) | 15.56 (9.19) | -10.8 (9.7) |
| Glottis (3)                                 | 0.43 (0.19) | 0.56 (0.15) | 0.14 (0.34) | 13.28 (7.63) | 8.58 (4.89) | -4.7 (12.3) |
| Mandible (6)                                | 0.88 (0.04) | 0.91 (0.02) | 0.03 (0.03) | 19.84 (8.59) | 6.75 (4.98) | -13.1 (8.8) |
| Pharyngeal constrictor muscles (8)         | 0.47 (0.16) | 0.59 (0.09) | 0.12 (0.12) | 30.34 (8.83) | 19.70 (3.65) | -10.6 (8.4) |
| Prophylactic PTV (19)                       | 0.70 (0.13) | 0.78 (0.05) | 0.07 (0.13) | 26.23 (16.33) | 15.64 (4.59) | -10.6 (17.1) |
| Therapeutic PTV (8)                         | 0.64 (0.15) | 0.70 (0.10) | 0.06 (0.11) | 11.14 (4.05) | 10.17 (2.31) | -1.0 (3.7) |
| Planning organ-at-risk volume of the spinal cord (3) | 0.78 (0.07) | 0.80 (0.09) | 0.01 (0.02) | 6.61 (2.73) | 6.68 (2.80) | 0.1 (1.1) |
| Supraglottic larynx (2)                     | 0.42 (0.31) | 0.41 (0.29) | -0.01 (0.02) | 21.03 (18.35) | 23.33 (15.09) | 2.3 (3.3) |
Table 2: Mean DSI and HD indexes for the final volumes

| Final volume                                      | DSI (SD) | HD (SD) |
|--------------------------------------------------|----------|---------|
| Planning organ-at-risk volume of the brainstem    | 0.79 (0.12) | 8.05 (2.59) |
| Cervical esophagus                                | 0.44 (0.22) | 18.20 (9.64) |
| Contralateral parotid                             | 0.81 (0.05) | 12.94 (5.27) |
| Cricoid pharyngeal inlet                          | 0.33 (0.16) | 12.93 (6.12) |
| Contralateral sub-mandibular gland                | 0.83 (0.06) | 7.02 (4.28) |
| Extended oral cavity-PTV                          | 0.86 (0.07) | 12.14 (6.13) |
| Glottis                                           | 0.56 (0.20) | 8.81 (4.28) |
| Ipsilateral parotid                               | 0.81 (0.04) | 11.71 (4.24) |
| Mandible                                          | 0.92 (0.02) | 7.52 (7.47) |
| Pharyngeal constrictor muscles                    | 0.62 (0.08) | 22.86 (17.28) |
| Prophylactic PTV                                  | 0.79 (0.06) | 16.05 (6.03) |
| Therapeutic PTV                                   | 0.74 (0.10) | 9.35 (3.47) |
| Planning organ-at-risk volume of the spinal cord  | 0.77 (0.13) | 12.52 (8.79) |
| Supraglottic larynx                               | 0.66 (0.16) | 11.58 (6.05) |
| Thyroid gland                                     | 0.86 (0.02) | 4.36 (1.20) |

Discussion

Thirty-five European institutions with in total 81 submitted benchmarks participated in this ancillary analysis inside an ongoing EORTC Head and neck trial. Hence, to our knowledge this represents the largest BC analysis in current literature among head and neck quality assurance programs. This analysis followed the suggestions on reporting items for studies on IOV in volume delineation made by Vinod et al. [22].

First, we could affirm that the major source of protocol variations relies on the delineation process, be it for OARs (53%) or target volumes (35%). This can be simply explained by a greater number of non-routing DARS required by the protocol. Considering each volume separately, pPTV was by far the major cause of rejection (24%). Several reasons could be identified as for example non protocol conformal selection of prophylactic lymph node regions, inadequate boundaries and inclusion of natural barriers inside the clinical target volume (CTV). These results are in par with the two other BC analysis inside the EORTC Head and neck Trials portfolio: In the EORTC 22071-26071 BC analysis, a trial evaluating the benefit of Panitumumab in addition to adjuvant chemoradiotherapy in locally advanced resected HNC revealed that 43.5% of the 23 submitted cases presented major protocol deviation on target volume delineations (CTVs, CTVs and PTVs) [11]. Additionally, Christiaens et al. published the EORTC 1219-Dahanca-29 BC analysis, an intergroup trial evaluating the influence of Nimorazole in patients with locally advanced head and neck cancer [23]. This work was done on 34 delineation BCs submitted by 19 centers. The authors reported a similar rejection rate of 63% (65% in our analysis). Furthermore, incorrect selection of prophylactic lymph node regions, were the major cause of rejection. This highlights the fact that elective nodal irradiation in terms of selection of LN regions and their corresponding delimitations still represents a major source of heterogeneity despite current guidelines. With regard to OAR delineations, in the EORTC 1219 BC trial, absence of contours represented the major reason for first refusal (10%). In our study, PCM was the principal reason for rejection. Only a minority (12%) of variations were due to planning issues.

After RTQA intervention, no notable difference could be detected in terms of mDSI. In the opposite, regarding mHD, an improvement in almost all volumes was observed. More precisely, in 5 out of 12 volumes, the mHD difference was even more than 10 mm. In the EORTC 1219 trial an improvement from the first to final submission in mDSI and mHD values was found to be increased for the prophylactic CTV (mDSI: 0.09 mHD: −11.6). On the other hand, the therapeutic CTV volume was only marginally improved (mDSI: 0.01; mHD: 0.4 mm). These findings were in par with our results highlighting an improvement for the prophylactic target volume of—10.6 (SD 17) in mHD and 0.07 in mDSI. Identically, the changes in therapeutic volume metrics were negligible. Furthermore, regarding the PCM, mHD increased by—10.6 (SD 17). Their seems to be a relationship between the rejected OARs and IOV improvement.
Fig. 1 Graphic representation on axial, sagittal and coronal planes of interobserver variation between institutions concerning the cricopharyngeal inlet (a), cervical esophagus (b), supraglottic larynx (c), therapeutic PTV (d) and glottis (e). The reference delineation is represented in blue outline.
Fig. 2 Boxplots of the Dice conformity Index and Hausdorff Index for each RT volume at final submission.
Table 3  Mean institutional dose distributions and dose requirements of the EORTC 1420 protocol for the different volumes

| Volumes                                      | Mean institutional doses (SD) | Dose requirements given by the EORTC 1420 Protocol |
|----------------------------------------------|-------------------------------|-----------------------------------------------------|
| Planning organ-at-risk volume of the brainstem | Dmax = 19.96 (9.12)          | Dmax < 35 Gy                                       |
| Cervical esophagus                          | Dmean = 14.75 (5.43)         | Dmean < 30 Gy                                      |
| Contralateral parotid                       | Dmean = 5.53 (1.79)          | Dmean < 5–10 Gy                                    |
| Cricoid pharyngeal inlet                    | D2% = 47.34 (6.98)           | D2% < 66 Gy                                       |
| Contralateral sub-mandibular gland          | Dmean = 7.82 (1.67)          | Dmean < 10 Gy                                      |
| Extended oral cavity-PTV                    | Dmean = 27.54 (4.66)         | Dmean < 30–35 Gy                                   |
| Glottis                                     | Dmean = 16.26 (3.56)         | Dmean < 20 Gy                                      |
| Ipsilateral parotid                         | Dmean = 25.60 (5.83)         | Dmean < 30–35 Gy                                   |
| Mandible                                    | D2% = 56.92 (4.59)           | D2% < 66 Gy                                       |
| Pharyngeal constrictor muscles              | Dmean = 33.75 (3.95)         | Dmean < 30–40 Gy                                   |
| Prophylactic PTV                            | D95% = 52.91 (0.81)          | D95% > 51.7 Gy                                     |
| Therapeutic PTV                             | D95% = 63.89 Gy (1.04)       | D95% > 62.7 Gy                                     |
| Planning organ-at-risk volume of the spinal cord | Dmax = 36.95 (4.05)       | Dmax < 40 Gy                                       |
| Supraglottic larynx                         | Dmean = 23.56 (4.90)         | Dmean < 45–50 Gy                                   |
| Thyroid gland                               | Dmean = 23.26 (2.05)         | Dmean < 25 Gy                                      |

Fig. 3  Dose variations received by RT volumes based on the protocol dose contraints

In particular prophylactic PTV and pharyngeal constrictor muscles, both figured among the most frequent causes of BC rejection and had their mHD improved by more than 10 mm. In the counterpart, therapeutic PTV improved after RTQA intervention but with a smaller margin even if represented by a relatively high rejection
rate. This is probably because changes in volume resubmissions are smaller.

The apparent discrepancy between both indexes relies on their different nature: The Dice coefficient is a volume-based metric and therefore commonly used to measure reproducibility. In the opposite, mHD index is part of the spatial distance-based metrics and consequently makes it especially interesting for highlighting the largest mismatch between the consensus contours and the submitted contours [24]. Therefore mHD is often more sensitive for benchmarking, simply by the fact that most critical sources of fluctuance, from an anatomical point of view derive from the upper and lower anatomical boundaries [25]. This criterion is most critical for longitudinal and narrow organs at risk as for example the CE and PCM and therefore mHD index is best fit to evaluate such discrepancies.

In addition, final mDSI and mHD metrics varied between 0.33 (cricopharyngeal inlet)—0.92 (mandible) and 22.86 (thyroid muscle) respectively. By choosing an aleatory threshold of 0.7 for mDSI and 15 mm for mHD, the CE-CPI-PCM-SL and glottis are in the highest risk IOV group for mDSI variability as the PCM-CE and prophylactic PTV are in the high IOV group for mHD variability. Furthermore, after excluding one single outlier of PCM, CE had the highest dispersion around the mean for both metrics (mDSI: 0.22; mHD: 9.64). In conclusion, these outcomes reinforce our hypothesis that new non-routine OARs in addition to the elective lymph node stations are at highest risk for IOV. Another hypothesis is that, due to low experience in non-routine OAR contouring, participating institutions tend to overestimate the true size of the organs.

In addition, in the EORTC 1219 DAHANCA BC analysis, the highest disagreement was observed for the larynx (mDSI/mHD 0.46 and 32.9) and oral cavity (mDSI/mHD: 0.49 and 19.08). This difference is increased in confrontation to our findings [(supraglottic larynx: mDSI/mHD: 0.66 and 11.58) and (oral cavity: mDSI/mHD: 0.86 and 12.14)]. This difference can be mainly explained by the fact that clear guidelines on organ at risk contouring were absent at that time.

Regarding the potential impact of volume IOV on dose distribution, no such evaluation could be made in our dataset as plans were created only in case volume acceptability was granted by the reviewers. However, in the EORTC 22071-26071 trial, the authors showed no statistically significant correlation between the PTV volume and the ability to meet parotid dose constraints ($p > 0.20$), neither between parotid contour acceptability nor meeting constraints ($p = 0.17$). Therefore, we hypothesize a low impact of IOV on dosimetry variations in case protocol requirements are fulfilled. Evaluating the potential impact of volume IOV on clinical outcomes, a review of several BC analysis realized among EORTC trials could not reveal any correlation between protocol conformal benchmarking and clinical results for a given trial [26].

Concerning the dose evaluation, no major difficulties were notified in reaching the given dose-constraints. Brainstem PRV was the most variable OAR. This finding is unsurprising as the brainstem tolerance in this protocol is far below the clinically recognized tolerance. Therefore, the participating institutions made no effort to optimize the dose to the brainstem.

Some limitations of this study should be mentioned: More accurate methods have been introduced since to estimate and reduce IOV, as the STAPLE (simultaneous truth and performance level estimation) algorithm [27]. This method is a validated formula which considers a collection of segmentations and estimates the ground truth based on the performance level by each segmentation. In addition, novel strategies for implementing OAR contouring guidelines at a national scale [28], visual atlases [29] and the use of digital platforms [30] have been proposed to further reduce IOV. Even more recently, artificial intelligence systems have been studied to simplify the workflow of radiotherapy [31]. In particular deep learning contouring (DLC) for Head and neck OARs were developed with satisfying preliminary results [32]. Indeed, DSI as mean and max dose difference were found to be significantly improved in 19 out of 22 OARs compared to the atlas based contouring (ABAS) by 0.15, 3.1 Gy and 3.3 Gy respectively [33]. The impact on dose distributions after Benchmark resubmissions could not be analyzed due to the internal process of planning once the volumes have been already been approved.

In conclusion, for this specific HNC trial with dysphagia as the primary endpoint and therefore critical relevance of correct delineation of not routinely delineated OARs, benchmarking was an effective tool to avoid protocol deviation and reduce IOV. On the other hand, in times of global increase of research costs, financing academic trials becomes a real challenge. We therefore recommend for future benchmark analyses an evaluation on the impact on dosimetry and clinical outcome as part of every trial initiation package [34].

Abbreviations

BC: Benchmark case; HPV: Human papilloma virus; IMRT: Intensity modulated radiation therapy; DARS: Dysphagia/aspiration related structures; MDADI: MD Anderson dysphagia inventory; RT: Radiotherapy; RTQA: Radiation therapy quality assurance; ROSHNC: Radiation oncologist specialized in head and neck cancer; GS: Gold standard; SIB: Simultaneous integrated boost; mDSI: Mean Sorensen–Dice similarity index; mHD: Mean percentile Hausdorff distance; OAR: Organs at risk; PCM: Parotid muscle; CE: Conjugate eye; SIB: Simultaneous integrated boost; mDSI: Mean Sorensen–Dice similarity index; mHD: Mean percentile Hausdorff distance; OAR: Organs at risk; PCM: Pharyngeal constrictor muscles; SD: Standard
deviations; CPI: Cricopharyngeal inlet; CE: Cervical esophagus; G: Glottis; SL: Supraglottic larynx; PRV: Planning at risk volume; Dmean: Mean dose; I/OV: Interobserver variability; CTV: Clinical target volume; pPTV: Prophylactic planning target volume.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13014-021-01809-2.

Additional file 1: BC description, protocol predefined criterions for BC review, and corresponding number of all unacceptable criterions.

Acknowledgements

This work has been supported by the “Vlaamse Liga tegen Kanker”, Belgium, through the EORTC Charitable Trust in the scope of the “Emmanuel van der Schueren” fellowship allocated to Jean-Jacques Stelmes in 2017-2018. The authors would like to thank the primary investigator Prof. Simon as well as Coreen Corning, the physicists and radiation technologists who contributed to the BC submissions from all the participating centers.

Authors’ contributions

J-J Stelmes: collected the data, wrote the paper, conceived and designed the analysis. E. Vu: collected the data, performed the analysis, contributed in writing the manuscript. V. Grégoire, conceived and designed the analysis. Christian Simon conceived and designed the analysis. Enrico Clementel: collected the data and designed the analysis. J. Kazmierska: contributed the data. F. Zimmerper: performed the analysis. E. C. Hurkmans: conceived the analysis. A. Branquinho: contributed the data. L. Vieillevigne: contributed the data. C. Fortpied: collected the data and designed the analysis. J. Kazmierska, C. Simon conceived and designed the analysis. E. Clementel: collected the data. K. Grant: contributed the data. M. Oszahind: contributed the data. M. Tomsej: contributed the data.

Competing interests

The authors and co-authors have no potential conflict of interest.

Acknowledgements

This work has been supported by the “Vlaamse Liga tegen Kanker”, Belgium, through the EORTC Charitable Trust in the scope of the “Emmanuel van der Schueren” fellowship allocated to Jean-Jacques Stelmes in 2017-2018. The authors would like to thank the primary investigator Prof. Simon as well as Coreen Corning, the physicists and radiation technologists who contributed to the BC submissions from all the participating centers.

Authors’ contributions

J-J Stelmes: collected the data, wrote the paper, conceived and designed the analysis. E. Vu: collected the data, performed the analysis, contributed in writing the manuscript. V. Grégoire, conceived and designed the analysis. Christian Simon conceived and designed the analysis. Enrico Clementel: collected the data and designed the analysis. J. Kazmierska, contributed the data. F. Zimmerper: performed the analysis. E. C. Hurkmans: conceived the analysis. A. Branquinho: collected the data. N. Andratschke: conceived the analysis. Frank Zimmerper: performed the analysis. E. C. Hurkmans: conceived the analysis. A. Branquinho: contributed the data. L. Vieillevigne: contributed the data. Catherine Fortpied: performed the analysis. E. C. Hurkmans: conceived the analysis. A. Branquinho: collected the data. N. Andratschke: conceived the analysis. Frank Zimmermann: conceived the analysis. D.C. Weber: wrote the paper, conceived and designed the analysis. All authors read and approved the final manuscript.

Funding

No funding source was necessary.

Availability of supporting data

Data is available at EORTC HQ, Brussels, Belgium.

Declaration

Ethical approval and consent to participate

Ethical Approval and Consent to participate is present for each institution participating in this trial.

Consent for publication

Full consent for publication is granted.

Competing interests

The author and co-authors have no potential conflict of interest.

Author details

1Radiation Oncology Department, Oncology Institute of Southern Switzerland, Via Athos Galliino 12, 6500 Bellinzona, Switzerland. 2Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 3Lyon University Hospital, Lyon, France. 4Lausanne University Hospital, Lausanne, Switzerland. 5EORTC Headquarters, Brussels, Belgium. 6Greater Poland Cancer Center, Poznan, Poland. 7Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK. 8Hospital of Charleroi, Charleroi, Belgium. 9Institut Claudius Regaud IUCT, Toulouse, France. 10Catharina Hospital, Eindhoven, The Netherlands. 11Centro Hospitalar Lisboa Norte, Lisbon, Portugal. 12University Hospital Zurich, Zurich, Switzerland. 13University Hospital of Basel, Basel, Switzerland. 14University Hospital of Bern, Bern, Switzerland. 15Paul-Scherer-Institute, Villigen, Switzerland.

Received: 11 March 2021 Accepted: 19 April 2021 Published online: 01 May 2021

References

1. Brenner H, Chalasani SB, Pulte D. Changes in survival in head and neck cancers in the late twentieth and early twenty-first centuries: a period analysis. J Clin Oncol. 2010;28:e12011–e12011. https://doi.org/10.1200/JCO.2010.28.15_suppl.e12011.
2. Haebroeck Michaelsen S, Grønhøj C, Haebroeck Michaelsen J, Friiborg J, von Buchwald C. Quality of life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366 patients. Eur J Cancer. 2017;78:91–102. https://doi.org/10.1016/j.ejca.2017.03.006.
3. Yeh DH, Tam S, Fung K, MacNeil SD, Yoo J, Winquist E, et al. Transoral robotic surgery vs radiotherapy for management of oropharyngeal squamous cell carcinoma—A systematic review of the literature. Eur J Surg Oncol (EJSO). 2015;41:1603–14. https://doi.org/10.1016/j.ejso.2015.09.007.
4. Rock K, O’Sullivan B, Chen Z-J, Xu Z-Y, Li J-S, Huang SH. Surgery- vs radiation-based therapy for p16+ HPV-related oropharyngeal cancers. Curr Oncol. 2018;26:9–27. https://doi.org/10.33999/TON.2018.04.024.
5. Nutting C, Rooney K, Foran B, Pettitt L, Beasley M, Finneran L, et al. Results of a randomized phase III trial of dysphagia-optimized intensity modulated radiotherapy (Do-IMRT) versus standard IMRT (S-IMRT) in head and neck cancer. J Clin Oncol. 2020;38:6508. https://doi.org/10.1200/JCO.2020.38.15_suppl.6508.
6. Stelmes J-J, Gregoire V, Poorten VV, Golusiñski W, Szewczyk M, Jones T, et al. Organ preservation and late functional outcome in oropharyngeal carcinoma: rationale of eortc 1420, the “best of” trial. Front Oncol. 2019. https://doi.org/10.3389/fonc.2019.00099.
7. Chen AY, Frankowski R, Bishop-Leone J, Hebert T, Levy S, Lewin J, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson Dysphagia Inventory. Arch Otolaryngol Head Neck Surg. 2001;127:870–6.
8. Poortmans PMP, Venselaar JLM, Struiksma H, Hurkmans CW, Davis JB, Huyskens D, et al. The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: A quality-assurance report on the dummy run of EORTC Phase III randomized trial 22922/10922 in Stage III breast cancer. Int J Radiat Oncol Biol Phys. 2001;49:1399–408. https://doi.org/10.1016/S0360-3016(00)01540-3.
9. Peters LJ, O’Sullivan B, Giralt J, Fitzgerald TJ, Torti A, Bernier J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TRG02.02. J Clin Oncol. 2010;28:2996–3001. https://doi.org/10.1200/JCO.2009.27.4498.
10. Matzinger O, Poortmans P, Giraud JV, Maingon P, Budhart T, van den Bergh ACM, et al. Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review. Radiother Oncol. 2009;90:285–90. https://doi.org/10.1016/j.radonc.2008.10.022.
11. Fairchild A, Langendijk JA, Nuys S, Scrase C, Tomsej M, Schuring D, et al. Quality assurance for the EORTC 22071–26071 study: dummy run prospective analysis. Radiat Oncol. 2014;9:248. https://doi.org/10.1186/s13014-014-0248-9.
12. Fenton PA, Hurkmans C, Gulyanab A, Van Der Leer J, Matzinger O, Poortmans P, et al. Quality assurance of the EORTC 22403–30401 trial in post-operative radiotherapy in prostate cancer: results of the dummy run procedure. Radiother Oncol. 2013;107:346–51. https://doi.org/10.1016/j.radonc.2013.04.020.
13. Weber DC, Poortmans PM, Hurkmans CW. Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicenter international setting. Radiother Oncol. 2011. https://doi.org/10.1016/j.radonc.2011.05.073.
14. Weber DC, Tomsej M, Melidis C. QA makes a clinical trial stronger: Evidence-based medicine in radiation therapy. Radiother Oncol. 2012. https://doi.org/10.1016/j.radonc.2012.08.008.
15. Brouwer CL, Steenbakkers RJM, Bourhis J, Budach W, Grau C, Grégoire V, et al. CT-based delineation of organs at risk in the head and neck region: validation target volume. Radiother Oncol. 2011;107(1):62–7. https://doi.org/10.1016/j.radonc.2011.05.073.
17. Blau J, Lapeyre M, Troussier I, Budach W, Giralt J, Grau C, et al. Selection of lymph node target volumes for definitive head and neck radiation therapy - a 2019 update. Radiother Oncol. 2019;134:1–9. https://doi.org/10.1016/j.radonc.2019.01.018.

18. Melidis C, Bosch WR, Izewska J, Fidarova E, Zubizarreta E, Ulin K, et al. Global harmonization of quality assurance naming conventions in radiation therapy clinical trials. Int J Radiat Oncol Biol Phys. 2014;90:1242–9. https://doi.org/10.1016/j.ijrobp.2014.08.348.

19. Melidis C, Bosch WR, Izewska J, Fidarova E, Zubizarreta E, Ishikura S, et al. Radiation therapy quality assurance in clinical trials - Global harmonisation group. Radiother Oncol. 2014;111:327–9. https://doi.org/10.1016/j.radonc.2014.03.023.

20. Herron DA. Gromov–Hausdorff distance for pointed metric spaces. J Anal. 2016;24:1–38. https://doi.org/10.1007/s14178-016-0001-x.

21. Zou KH, Warfield SK, Bharatha A, Tempany CMC, Kaus MR, Haker SJ, et al. Overlap index1: scientific reports. Acad Radiol. 2004;11:178–89. https://doi.org/10.1016/S1097-6332(03)00671-8.

22. Vinod SK, Jameson MG, Min M, Holloway LC. Uncertainties in volume delineation in radiation oncology: A systematic review and recommendations for future studies. Radiother Oncol. 2016;121:169–79. https://doi.org/10.1016/j.radonc.2016.09.023.

23. Christiaens M, Collette S, Overgaard J, Gregoire V, Kazmierska J, Cast-adot P, et al. Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: results of the benchmark case procedure. Radiother Oncol. 2017. https://doi.org/10.1016/j.radonc.2017.04.019.

24. Taha AA, Hanbury A. SOFTWARE Open Access Metrics for evaluating 3D medical image segmentation: analysis, selection, and tool. BMC Med. 2015;15:29. https://doi.org/10.1186/s12880-015-0068-x.

25. Brouwer CL, Steenbakkers RJHM, Van den Heuvel E, Duppen JC, Navran A, Bijl HP, et al. 3D variation in delineation of head and neck organs at risk. Radiat Oncol. 2012. https://doi.org/10.1186/1748-717X-7-32.

26. Fairchild A, Collette L, Hurkmans CW, Baumert B, Weber DC, Gulyban A, et al. Do results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials? Eur J Cancer. 2012;48:2323–9. https://doi.org/10.1016/j.ejca.2012.06.002.

27. Warfield SK, Zou KH, Wells WM. Simultaneous truth and performance level estimation (STAPLE): an algorithm for the validation of image segmentation. IEEE Trans Med Imaging. 2004;23:903–21. https://doi.org/10.1109/tmi.2004.828354.

28. Olsson C, Nyholm T, Wieslander E, Onjukka E, Gunnlaugsson A, Reizenstein J, et al. Initial experience with introducing national guidelines for CT- and MR-based delineation of organs at risk in radiotherapy. Phys Imaging Radiat Oncol. 2019;11:88–91. https://doi.org/10.1016/j.phoro.2019.08.006.

29. Fuller CD, Nijkamp J, Duppen JC, Rasch CRN, Thomas CR, Wang SJ, et al. Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting. Int J Radiat Oncol Biol Phys. 2011;79:481–9. https://doi.org/10.1016/j.ijrobp.2009.11.012.

30. Franco P, Arcadipane F, Trino E, Gallo E, Martini S, Iorio GC, et al. Variability of clinical target volume delineation for rectal cancer patients planned for neoadjuvant radiotherapy with the aid of the platform Anatom-e. Clin Transl Radiat Oncol. 2018;11:33–9. https://doi.org/10.1016/j.ctra.2018.06.002.

31. Francolìni G, Desideri I, Stocchi G, Salvestrini V, Ciccone LP, Garlatti P, et al. Artificial intelligence in radiotherapy: state of the art and future directions. Med Oncol. 2020;37:1–9. https://doi.org/10.1007/s12032-020-01374-w.

32. van Rooij W, Dahele M, Ribeiro Brandao H, Delaney AR, Slotman BJ, Verbakel WP. Deep learning-based delineation of head and neck organs at risk: geometric and dosimetric evaluation. Int J Radiat Oncol Biol Phys. 2019;104:677–84. https://doi.org/10.1016/j.ijrobp.2019.02.040.

33. van Dijk LV, Van den Bosch L, Aljabar P, Peressutti D, Both S, Steenbakkers Roel JHM, et al. Improving automatic delineation for head and neck organs at risk by Deep Learning Contouring. Radiother Oncol. 2020;142:115–23. https://doi.org/10.1016/j.radonc.2019.09.022.

34. Cox S, Cleves A, Clementel E, Miles E, Stafford J, Gwynne S. Impact of deviations in target volume delineation—Time for a new RTQA approach? Radiother Oncol. 2019;137:1–8. https://doi.org/10.1016/j.radonc.2019.04.012.